Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VOLGA phase 3 perioperative durvalumab + tremelimumab and/or enfortumab vedotin for cisplatin-ineligible muscle-invasive bladder cancer
MOH_2022-04-27_010755Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Feb 2022
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of durvalumab, tremelimumab, enfortumab vedotin and nivolumab in bladder cancer and transitional cell carcinoma (TCC) (3 arms), sponsored by AstraZeneca. Started Feb 2022; status: recruiting.
02
Drugs
03
Conditions
bladder cancertransitional cell carcinoma (TCC)
Beyond the preview
Go deeper on MOH_2022-04-27_010755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-04-27_010755.